Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Blogs > Disease > Could the gut microbiome help manage diabetes?

Could the gut microbiome help manage diabetes?

June 10, 2019 | Disease

Melanie senior

Diabetes remains one of the most prevalent and costliest disorders, despite a wide palette of available treatments.

Leading diabetes players continue to churn out more convenient versions of their drugs, grappling for share in a highly competitive, price-pressured market.  Novo Nordisk recently invested in a short-cut route-to-market for its oral GLP-1 agonist, semaglutide, buying a priority review voucher from another company that may allow it to launch three months earlier.

GLP-1 agonists, like Novo’s own once-daily injectable, Victoza, have proven effective among many thousands of patients. They can help delay patients’ move onto insulin, and are much easier to use.

But the growth in diabetes prevalence means that new approaches are needed. Drugs are effective when they’re taken properly, but most often, they aren’t. Technology is helping – “intelligent” insulin pens, connected glucose monitors and apps to encourage healthy behavior and medication adherence are proliferating. The diabetes challenge has also drawn in behavioural psychologists and urban planners.

The gut microbiome may be the next frontier in battling diabetes. Research is uncovering a key role for the gut flora in many diseases, not just gastro-intestinal conditions but also cancers, auto-immune, endocrine and even central nervous system disorders. Gut bacteria are now understood to communicate with the brain and influence behavior – including, in some cases, by generating neurotransmitters like serotonin, gamma-aminobutyric acid (GABA) or dopamine.

An imbalance in the gut microbiome has already been associated with the development of insulin resistance in Type 2 (acquired) diabetes. Shifts in the gut microbiota can alter host metabolism – shifting it toward greater energy-harvesting and fat-deposition, for instance, or, potentially, driving appetite even when energy stores are replete.

The precise mechanisms and molecules involved, along with causal links, remain to be figured out. But it seems intuitive that gut health will impact diabetes, not least as this is a disease exacerbated by a high-fat diet. If, as is now believed, the gut influences behavior too, then a gut-microbiome-targeted approach could provide an effective solution for the many diabetics who cannot control their condition using existing therapies and tools.

Novo has been working since mid-2018 with Kallyope to uncover novel peptides to treat diabetes and obesity. New York City-based Kallyope is one of a handful of biotech companies seeking new therapeutic approaches through harnessing the “gut-brain axis” – the multiple two-way communication channels (neuronal, endocrine and humoral) between head and stomach.

The effort is still in discovery. But if drugs or nutritional supplements could be found that modulate both physiology (blood sugar regulation, energy homeostasis, insulin resistance) and psychology (appetite, willpower), this could prove a very useful addition to the diabetes toolbox.  

TargEDys in France already markets an appetite-regulating probiotic, ProbioSatys. Available over-the-counter, it allegedly promotes a feeling of fullness by providing a protein, ClpB, which mimics a satiety hormone called alpha-MSH. ClpB is produced naturally by certain types of gut bacteria. Its action is two-pronged – it enters the blood stream to act directly on the central nervous system, but also stimulates intestinal endocrine cells to produce more alpha-MSH. ProbioSatys is designed to enhance those natural regulatory pathways.

A trial is underway among 236 overweight people, to assess the supplement’s impact on weight, as well as its tolerability and safety, over a 12-week period versus placebo. The estimated completion date is August 2019, according to clinicaltrials.gov.

Related Content

Diabetic Nephropathy Market Forecast Analysis 2037
Datamonitor Healthcare Type 2 Diabetes KOL Interview - Italy
Diabetes Type 1

FacebookTweetPin

Related posts:

Coronavirus: A catalyst for digital health?
Disease

Coronavirus: A catalyst for digital health?

  • March, 20 2020
  • 1575

Every cloud has a silver lining. Coronavirus will be the same. One of its silver linings may be faster uptake of digital health tools and gadgets, as individuals are compelled to remain at home amid one of the century’s most concerning pandemics.   

More Options for Ovarian cancer
Disease

More Options for Ovarian cancer

  • March, 17 2020
  • 1037

One in 78 women will suffer from ovarian cancer during their lifetime. The condition accounts for more deaths than any other cancer of the reproductive system – and ranks fifth in overall cancer deaths among women.  The good news is that the range

The Big 2020 Challenge
Disease

The Big 2020 Challenge

  • January, 16 2020
  • 2152

Over the last three decades, the biotechnology industry has transformed our medicines cabinet, bringing new, effective treatments for a range of unmet needs, from rare genetic conditions, to stubborn cancers and debilitating chronic diseases. Yet several

Related Content
Read more
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Datamonitor Healthcare is part of Pharma intelligence Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
Cervical cancer screening comes to your mobile phone Hepatitis drugs are effective and ever-cheaper. Yet the disease still kills...

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
  • Informa PLC
  • ABOUT US
  • INVESTOR RELATIONS
  • TALENT
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726
informa
Call Back
Scroll to top